Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Are you Dr. Renschler?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Markus Renschler, MD is an oncologist in Stanford, California. He is currently licensed to practice medicine in California.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1988 - 1989
Stanford University School of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 1989 - 2026
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 5 citations18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer.Ronald L. Korn, Daniel D. Von Hoff, Mitesh J. Borad, Markus F. Renschler, Desmond McGovern
Cancer Imaging. 2017-08-03 - Letter to the Editor Re: Ahn DH, Krishna K, Blazer M,. "A modified regimen of biweekly gemcitabine and-paclitaxel in patients with metastatic pancreatic cancer is both...Daniel D Von Hoff, Markus F Renschler
Therapeutic Advances in Medical Oncology. 2017-06-01 - 22 citationsTumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 StudyVolker Kunzmann, Ramesh K. Ramanathan, David Goldstein, Helen Liu, Stefano Ferrara
Pancreas. 2017-02-01
Press Mentions
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic MalignanciesJune 5th, 2022- Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of DirectorsDecember 16th, 2021
- Cyteir Therapeutics Selected to Join Russell 2000® IndexSeptember 20th, 2021
- Join now to see all
